- Conditions
- Eosinophilic Gastritis, Eosinophilic Gastroenteritis
- Interventions
- AK002, Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 117
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypercholesterolemia
- Interventions
- Evinacumab, Matching placebo, Background Lipid Modifying Therapy (LMT)
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more
- Conditions
- Gastroenteritis
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years to 76 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- dupilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 754 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Mullica Hill, New Jersey
- Conditions
- Churg-Strauss Syndrome
- Interventions
- Mepolizumab, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Chronic Tympanic Membrane Perforation
- Interventions
- ASP0598, Placebo
- Drug · Other
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 10
- States / cities
- Palo Alto, California • Torrance, California • Boca Raton, Florida + 7 more
- Conditions
- Eosinophilic Duodenitis, Eosinophilic Gastroenteritis
- Interventions
- AK002, Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Chula Vista, California + 35 more
- Conditions
- Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
- Interventions
- benralizumab, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Graft-versus-Host Disease
- Interventions
- Methoxsalen+ECP, Methylprednisolone, Ecp
- Drug · Procedure
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Ann Arbor, Michigan • New York, New York + 2 more
- Conditions
- Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
- Interventions
- INZ-701
- Drug
- Lead sponsor
- Inozyme Pharma
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Eatontown, New Jersey
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Mucosal Impedance, Upper Endoscopy
- Device · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Adolescent Idiopathic Scoliosis
- Interventions
- EOS® imaging system
- Device
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Spinal Deformity
- Interventions
- ATEC IntraOperative Alignment (IOA) Imaging Platform, Standard 36" cassette imaging, EOS radiographs
- Diagnostic Test
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obesity, Insulin Resistance
- Interventions
- endoscopy sleeve gastroplasty
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- SLE, Lupus, Systemic Lupus Erthematosus, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE)
- Interventions
- Physical examination, Electrocardiogram, SF-36 questionnaire, Clinical laboratory evaluations - Serology, Clinical laboratory evaluations - Biochemistry, Clinical laboratory evaluations - Hematology, Pregnancy Test, Urinalysis, SLE activity evaluation, SLE biomarker profiling, Cytokines and chemokine profiling, single dose of UC-MSCs, PROMIS instruments
- Diagnostic Test · Other · Biological
- Lead sponsor
- LiveKidney.Bio
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Computerized Tomography scan, Single Photon Emission Computed Tomography scans, Technetium Tc 99M, Planar Images, Esophagogastroduodenoscopy
- Radiation · Drug · Procedure
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Scoliosis
- Interventions
- spineEOS software, EOS
- Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 10 Years to 80 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypereosinophilic Syndrome
- Interventions
- SCH55700
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran sodium 300 mg, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 17,004 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 271
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 214 more
- Conditions
- Chronic Kidney Diseases
- Interventions
- Bardoxolone methyl oral capsule, Placebo oral capsule
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 12
- States / cities
- La Mesa, California • Arvada, Colorado • Denver, Colorado + 9 more
- Conditions
- Alveolar Bone Loss
- Interventions
- INFUSE® Bone Graft
- Device
- Lead sponsor
- Medtronic Spinal and Biologics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Loma Linda, California • Los Angeles, California • Sarasota, Florida + 3 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Retrospective evaluation of endoscopy prior to study drug, Symptom Survey, Medication Compliance Phone Call, Endoscopy while on study drug, Fluticasone, Omeprazole, Placebo oral capsule
- Diagnostic Test · Other · Drug
- Lead sponsor
- Claire Daniels
- Federal
- Eligibility
- 6 Years to 60 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Eosinophilic Gastritis, Eosinophilic Duodenitis
- Interventions
- lirentelimab (AK002), Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 54 more
- Conditions
- Schizophrenia
- Interventions
- Intervention Active tDCS
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 8 Years to 25 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio